science
Bristol Myers Squibb Partners With Hengrui Pharma on Early-Stage Programs
Bristol Myers Squibb announced a partnership with Hengrui Pharma covering more than a dozen early-stage programs. The agreement is the latest instance of a global pharmaceutical company seeking medicines from China. Separately, Viiv lost an HIV treatment patent case while other companies reported regulatory and commercialization developments.
May 12, 3:30 PM·1m read1 source
manilatimes.netAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Bristol Myers Squibb announced a partnership with Hengrui Pharma covering more than a dozen early-stage programs. The deal represents the latest and notably large example of a global pharmaceutical company looking to China for its next medicines, according to a report published Tuesday.
The company did not disclose further financial terms of the agreement in the initial announcement. The partnership aims to restock Bristol Myers Squibb's early-stage pipeline.
Pharma will market the newly approved breast cancer drug Veppanu under a commercialization agreement signed with Arvinas and Pfizer. Roche received European clearance for a new blood test designed to detect early Alzheimer’s disease. BridgeBio submitted an application to the FDA seeking approval of its drug encaleret to treat patients with autosomal dominant hypocalcemia type 1, also known as ADH1.
The rare genetic disease causes low calcium levels in the blood.
Additional News Viiv lost an HIV treatment case.
Hims reported sales that missed expectations as telehealth competition grows. A series investigating the alcohol epidemic in the U.S. launched on the same day. The stories examine factors ranging from the influence of the alcohol industry to gaps in treatment options for addiction.
